AtonRa Partners’s Avidity Biosciences RNAM Stock Holding History

AtonRa Partners’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$152K	Sell	16,834 -2,136	-11%	-$14.3K	0.3%	116
2023 Q3	$121K	Sell	18,970 -3,468	-15%	-$29.9K	0.25%	120
2023 Q2	$249K	Sell	22,438 -2,077	-8%	-$26.1K	0.39%	109
2023 Q1	$376K	Sell	24,515 -2,262	-8%	-$49.8K	0.55%	85
2022 Q4	$594K	Sell	26,777 -7,242	-21%	-$108K	0.76%	60
2022 Q3	$556K	Sell	34,019 -627	-2%	-$12K	0.55%	84
2022 Q2	$503K	Sell	34,646 -5,473	-14%	-$81.4K	0.46%	99
2022 Q1	$741K	Buy	40,119 +2,297	+6%	+$39K	0.4%	90
2021 Q4	$899K	Buy	+37,822	New	+$903K	0.31%	97

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AtonRa Partners's RNAM Position: Q4 2023 in Review

AtonRa Partners reduced its Avidity Biosciences (RNAM) stake by 11% in Q4 2023, selling an estimated $14.3K and leaving 16,834 shares worth $152K. The position accounts for 0.3% of the portfolio, ranked #116.

AtonRa Partners first reported a position in RNAM in Q4 2021 and has held it in 9 quarters since. The position peaked at $899K in Q4 2021. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

AtonRa Partners held 16,834 shares of Avidity Biosciences worth $152K as of Q4 2023.
AtonRa Partners sold 2,136 Avidity Biosciences shares in Q4 2023, an estimated $14.3K.
Avidity Biosciences made up 0.3% of AtonRa Partners's portfolio in Q4 2023, its #116 holding.
AtonRa Partners first reported a position in Avidity Biosciences in Q4 2021 and has held it in 9 quarters since.
AtonRa Partners's Avidity Biosciences position peaked at $899K in Q4 2021.
144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.